"Zalospirone"

an anxiety disorder diagnosis, iii) subject with anxiety as a specifier of another psychiatric condition and not primarily diagnosed.Intervention(s), exposure(s)Inclusion criteria: i) any azapirone (e.g., alnespirone, binospirone, buspirone, enilospirone, eptaspirone, gepirone, ipsapirone, revospirone, tandospirone, zalospirone), ii) any route of administration (e.g., oral, transdermal, others)Exclusion of Bias assessment will be presented in the discussion.Analysis of subgroups or subsetsRegarding efficacy analyses, we will perform subgroup analyses, considering different molecules (e.g., alnespirone, binospirone, buspirone, enilospirone, eptaspirone, gepirone, ipsapirone, revospirone, tandospirone, zalospirone), considering different comparators (e.g., SSRI, TCA, single molecules), when

populationsIntervention(s), exposure(s)Inclusion criteria: i) azapirones (e.g., alnespirone, binospirone, buspirone, enilospirone, eptaspirone, gepirone, ipsapirone, revospirone, tandospirone, zalospirone)Exclusion criteria: i) non-azapirone drugsComparator(s)/controlInclusion criteria: i) placebo ii) other active pharmacological treatments iii) Therapy as usual for augmentation trialsExclusion criteria: i

Zalospirone in major depression: a placebo-controlled multicenter study. Compounds active at the serotonin (5-HT)1A receptor (mostly azapirones) have shown some evidence of antidepressant effect. We report here the results of an antidepressant trial with zalospirone, a novel cyclic imide with 5-HT1A partial agonist activity. Two hundred eighty-seven outpatients (mean age 44 years, 55% men, 45 % nonfertile women) who met criteria for unipolar major depression with a minimum 21-item Hamilton Rating Scale for Depression (HAM-D) score of 20 were randomly assigned to receive 6 weeks of double-blind treatment with either placebo or one of three fixed doses of zalospirone (6, 15, or 45 mg/day), administered three times daily. The high dose (45 mg) of zalospirone produced a significant antidepressant